Mark C. Enright
Corporate Officer/Principal presso Imperial College London
Profilo
Mark C.
Enright is a Professor at Imperial College London since 2007.
He previously worked as a Research Director at AmpliPhi Biosciences Corp.
and Biocontrol Ltd.
(United Kingdom).
He obtained a doctorate degree from the University of Aberdeen.
Posizioni attive di Mark C. Enright
| Società | Posizione | Inizio |
|---|---|---|
| Imperial College London | Corporate Officer/Principal | 31/10/2011 |
Precedenti posizioni note di Mark C. Enright
| Società | Posizione | Fine |
|---|---|---|
Biocontrol Ltd. (United Kingdom)
 Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | - |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Mark C. Enright
| University of Aberdeen | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Biocontrol Ltd. (United Kingdom)
Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Mark C. Enright
